You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥(600196.SH)近期股價漲幅較大 新冠mRNA疫苗尚處於I期臨牀試驗啟動階段
格隆匯 07-27 18:40

格隆匯 7 月 27日丨復星醫藥(600196.SH)公佈,公司A股票2020723日、724727連續個交易日收盤價格漲幅偏離值累計超過20%

公司控股子公司上海復星醫藥產業發展有限公司(“復星醫藥產業”)BioNTech SE (“BioNTech”)許可的用於預防新型冠狀病毒肺mRNA疫苗(BNT162b1)(“該疫苗”或“新冠mRNA疫苗”)國家藥品監督管理局(“國家藥監局)批准於中國境內(不包括港澳台地區,下同)開展臨牀試驗截至公告日,該疫苗於中國境內尚處於I期臨牀試驗啟動階段

根據目前中國境內關於疫苗產品的審批要求疫苗研發經驗該疫苗尚需成臨牀I期、II期和/III期試驗、上市批准、生產設施認證/核查(如適用)等主要環節且受到諸多不確定因素影響。因此,該疫苗中國境內能否獲得相關藥品監管機構(包括但不限於國家藥監局)的上市批准、獲得上市批准的時間等,存在不確定性。

除上述事項以及公司公告已披露的信息外經自查,未發現對公司A股票交易價格可能產生重大影響的媒體報道或市場傳聞

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account